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Abstract
Background: Patients diagnosed with idiopathic mild to moderate carpal tunnel syndrome (CTS) are usually managed
in primary care and commonly treated with night splints and/or corticosteroid injection. The comparative effectiveness
of these interventions has not been reliably established nor investigated in the medium and long term. The primary
objective of this trial is to investigate whether corticosteroid injection is effective in reducing symptoms and improving
hand function in mild to moderate CTS over 6 weeks when compared with night splints. Secondary objectives are to
determine specified comparative clinical outcomes and cost effectiveness of corticosteroid injection over 6 and
24 months.
Method/Design: A multicentre, randomised, parallel group, clinical pragmatic trial will recruit 240 adults
aged ≥18 years with mild to moderate CTS from GP Practices and Primary-Secondary Care Musculoskeletal
Interface Clinics. Diagnosis will be by standardised clinical assessment. Participants will be randomised on an
equal basis to receive either one injection of 20 mg Depo-Medrone or a night splint to be worn for 6 weeks. The primary
outcome is the overall score of the Boston Carpal Tunnel Questionnaire (BCTQ) at 6 weeks. Secondary outcomes are the
BCTQ symptom severity and function status subscales, symptom intensity, interrupted sleep, adherence to
splinting, perceived benefit and satisfaction with treatment, work absence and reduction in work performance,
EQ-5D-5L, referral to surgery and health utilisation costs. Participants will be assessed at baseline and followed
up at 6 weeks, 6, 12 and 24 months. The primary analysis will use an intention to treat (ITT) approach and multiple
imputation for missing data. The sample size was calculated to detect a 15 % greater improvement in the BTCQ overall
score in the injection group compared to night-splinting at approximately 90 % power, 5 % two-tailed significance and
allows for 15 % loss to follow-up.
Discussion: The trial makes an important contribution to the evidence base available to support effective conservative
management of CTS in primary care. No previous trials have directly compared these treatments for CTS in primary care
populations, reported on clinical effectiveness at more than 6 months nor compared cost effectiveness of the
interventions.
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Background
Carpal tunnel syndrome (CTS) is caused by compression
of the median nerve as it passes through the carpal tun-
nel [1]. CTS leads to difficulties with day-to-day tasks
and reduces capacity to work impacting on quality of life
and general health [2–4]. Incidence rates in the general
population have been estimated at 61–120 per 100,000
women and 35–60 per 100,000 men per year [5].
CTS is characterised by pain, paraesthesia and numb-
ness in the median nerve distribution; usually worse at
night causing sleep disruption, and may be alleviated by
shaking the hand. Over half of patients have bilateral
symptoms and the age distribution is bimodal peaking in
the 50–54 and 75–84 age groups [1, 5–8].
There is no consensus on the best treatment for CTS,
especially in primary care [9]. Surgical decompression is
often considered the definitive solution to resolve symp-
toms in severe or unresponsive cases. Systematic review
evidence comparing surgical with non-surgical treat-
ments concluded that surgery produced superior results
to splinting, but evidence for the benefit of surgery over
corticosteroid injection was unclear [10]. In patients
who have surgery up to 8 % are left with worse or unim-
proved symptoms [11].
The most commonly used treatments for mild/moderate
CTS in primary care are splinting, anti-inflammatory medi-
cation and local corticosteroid injection [9, 12]. Systematic
reviews of these treatments [9, 13–15] draw similar conclu-
sions of moderate evidence in the short term for nocturnal
hand bracing/splinting being more effective than no ther-
apy (relative risk for overall improvement in symptom and
function = 4.00; 95 % CI, 2.34–6.84) with limited evidence
of medium term effects [9] and moderate to strong evi-
dence for the effectiveness of corticosteroid injections over
placebo (relative risk in terms of success rate: 2.58; 95 % CI,
1.72–3.87) in the short term [9]. In one primary study [16]
of corticosteroid injections, higher doses (60 mg) appeared
more effective than lower doses (20 or 40 mg) in the
medium term (success rates for high dose 73 % versus 53-
56 %) although the benefits were not maintained in the
long term. Two injections of 15 mg steroid did not provide
any additional clinical benefit over a single treatment [9].
Review authors conclude that many of the included trials
had a high risk of bias and recommended that more robust
trials are needed to compare treatments and ascertain the
medium to long-term benefits [9, 13–15].
The effects of corticosteroid injection and splinting have
been compared in two small trials, neither of which were
carried out in a primary care setting. Sevim and colleagues
showed superior effects of splinting over corticosteroid in-
jection (n = 30) [17] and Ucan et al. found no significant
differences in clinical outcome when comparing splinting
(23 hands) to a combination of injection with splinting (23
hands) although both groups improved [18]. Robust infer-
ences cannot be made from these studies.
We have therefore designed and are currently imple-
menting a prospective randomised clinical trial to directly
compare the clinical and cost-effectiveness of night splint-
ing and corticosteroid injections as primary care manage-
ment interventions for CTS.
Methods
Aim
The primary objective of the INSTINCTS trial is to in-
vestigate whether a corticosteroid injection is clinically
effective in reducing symptoms and improving function
in the short term (6 weeks) compared to a resting night
splint in people consulting with mild to moderate carpal
tunnel syndrome in primary care.
The secondary objectives are to examine clinical and
cost effectiveness in the medium term (6 months) of a
single corticosteroid injection compared to night splinting,
from a healthcare (NHS) and personal social services per-
spective as well as from a societal perspective to include
the differences in productivity loss. In the longer term
(24 months) we will examine differences in symptoms,
function, work absence, and other health care resource
use, in particular, referral for CTS surgery.
Design
The trial is a randomised, multicentre, open label, parallel
group, pragmatic clinical trial comparing a single injection
of Methylprednisolone Acetate (as 20 mg of Depo-
Medrone 40 mg/ml) into the carpal tunnel versus
6 weeks of night splinting in patients with mild to mod-
erate CTS.
Eligibility criteria
The eligibility criteria (Table 1) are designed to select a
relatively homogeneous group of patients with CTS,
suitable for both splinting and local injection and who
do not require immediate onward referral for surgery.
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For participants with bilateral CTS a study hand will be
designated by the participant based on the most severe
symptoms. Patients will not be allowed to enter the trial
more than once.
Inclusion criteria
The study population will consist of adults aged 18 years
and over with a new episode of primary idiopathic mild
to moderate CTS which has been present for more than
6 weeks. Clinical diagnosis will be made by a GP or
trained clinician and standardised based on presenting
symptoms, clinical history and physical tests using criteria
developed as part of a consensus survey of GPs from the
UK Primary Care Rheumatology Society [12]. Mild CTS is
defined as intermittent paraesthesia in the distribution of
the median nerve and moderate as constant paraesthesia,
reversible numbness and/or pain of idiopathic nature [19].
Exclusion criteria
Participants will be ineligible for the trial if they have re-
ceived either a corticosteroid injection or night splints
for CTS within preceding 6 months or had previous sur-
gery in the affected wrist (or study wrist in the case of
bilateral symptoms), severe CTS exhibiting constant
numbness or pain, constant sensory loss, severe thenar
muscle atrophy or symptom severity which requires the
patient to be referred for a surgical opinion. Other ex-
clusion criteria are listed in Table 1.
Recruitment, screening process and enrolment
Participants will be recruited from up to 50 sites includ-
ing; GP practices, primary-secondary care musculoskeletal
interface clinics throughout the UK. Research sites will
have received NHS permission and trial specific training
covering the interventions and trial administrative proce-
dures (Additional file 1).
General practice recruitment
For patients consulting in general practice, who are diag-
nosed with mild-moderate CTS and are eligible to partici-
pate, information about the trial will initially be provided
verbally by their GP. Interested eligible patients will be
given a participant information leaflet. Patients will be
asked to give written consent to provide their personal
details to Keele University. This will permit contact by a
Clinical Research Network Nurse who will provide a full
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Male or female aged ≥ 18 years Corticosteroid injection or night splints for CTS in the affected wrist within
preceding 6 months
A clinical diagnosis of unilateral or bilateral CTS as made by a GP
or trained clinician according to the diagnostic criteria
Severe CTS exhibiting constant numbness or pain, constant sensory loss, severe
Thenar muscle atrophy or symptom severity which requires the patient to be
referred for a surgical opinion
Mild (e.g. intermittent paraesthesia) or moderate (e.g. constant
paraesthesia, reversible numbness and/or pain) severity CTS of
idiopathic nature
Any previous surgery on the affected wrist (or study wrist in the case of bilateral
symptoms)
Symptom duration of episode of at least 6 weeks Clinical suspicion of local or systemic sepsis or infection
Written informed consent provided by the patient, prior to any
trial specific procedures
Current or previous infection of the affected wrist
Trauma to the affected hand requiring surgery or immobilisation in the previous
12 months
Unable to tolerate the study interventions
Unable to understand and complete self-report questionnaires written in English
Inter-current illness including, but not limited to:
• poorly controlled thyroid disease
• poorly controlled diabetes mellitus
• vibration-induced neuropathy
• inflammatory joint disease
• suspected complex neurological conditions
• any other severe medical illness which in the opinion of the local Principal
Investigator (or other authorised clinical delegate) precludes trial participation
Pregnant or lactating females
Receiving anticoagulants
Any history of hypersensitivity to Depo-Medrone or any of its excipients
Allergy to any of the splint materials
Known abuse of drugs or alcohol
Involved in on-going litigation cases for their condition
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verbal explanation of the trial for the patient to consider.
This will include detailed information about the rationale,
design and personal implications of the trial. The patients
will be advised by the GP that consent to contact does not
oblige them to take part in the trial. For patients willing to
participate, a second appointment for randomisation and
treatment with the treating clinician will be made (within
a minimum of 24 h and a maximum of 4 weeks’ time). On
attendance at their scheduled second appointment, the
patient’s GP will check for continued eligibility for
inclusion and gain written informed consent to study
participation from those eligible patients willing to take
part in the study.
Primary/Secondary care musculoskeletal interface clinics
recruitment
For patients consulting at musculoskeletal interface or
similar clinics based in secondary care, patients will be
informed verbally about the trial by a study clinician fol-
lowing an initial clinical assessment. Eligible patients who
are interested will be provided with an information leaflet.
When the patient has had adequate time to read the infor-
mation, a study clinician will give full details of the trial
and answer any questions. Those patients willing to take
part will be required to provide full written consent. A list
of sites at which patients will be recruited is provided as
Additional file 1.
Randomisation
Prior to randomisation all participants will complete the
baseline questionnaire, which includes questions regarding
sociodemographic characteristics, outcome measures and
potential prognostic factors. Participants will be rando-
mised by the local clinician, in a 1:1 ratio via a remote web
based randomisation system, which ensures the allocation
sequence is concealed. The randomisation sequence is
based on computer generated, random permuted blocks
of sizes 2 and 4 and will be blocked by research site. Fol-
lowing completion of randomisation patients will be given
a patient card detailing their treatment allocation, which
they are asked to carry at all times during the first 6 weeks
and to present it to medical staff should they be admitted
to hospital during this time on the study.
Blinding
Blinding of participants and practitioners is not possible
due to the study design. Group allocation will however be
concealed to both parties prior to randomisation. Both
primary and secondary outcomes are based on self-report
questionnaires therefore there will be no investigator bias
introduced at assessment stage. Analysis at the primary
end point will be conducted blind to group allocation.
Interventions
To reflect the consensus regarding usual practice for
administering corticosteroid injection for CTS in primary
care, participants randomised to injection will receive one
injection of 20 mg of Depo-Medrone (from 40 mg/ml) via
a disposable needle (23 or 25G) and syringe. This will be
inserted at the wrist to infiltrate the carpal tunnel. A sterile
‘no-touch’ technique will be used and the addition of local
anaesthetic is not permitted. The patient will sit with the
hand placed palm upwards in a neutral or slightly extended
wrist position. The skin is cleaned according to local policy
and the needle inserted between the proximal and distal
skin creases at the wrist, preferably on the ulnar side of the
Palmaris longus which lies over the median nerve. The
needle is angled at 45 degrees distally to enter the carpal
tunnel. Occasionally, due to anatomical variations, e.g.
large superficial veins, the injection may be given on the
radial side of the Palmaris longus. Injections into the palm
of the hand are not permitted as there are rare reports of
ischaemic necrosis of the fingertips presumably due to the
needle penetrating the palmar arterial arch. Participants
will be advised to wait for 30 min following injection and
to rest the injected arm for 48 h. They will be given two
Arthritis Research UK patient leaflets: “Carpal tunnel
syndrome” and “Local corticosteroid injections”. No
other additional types of therapy are advised during the
6 week treatment period except for simple analgesia
prescribed by the treating clinician or bought over the
counter (e.g. paracetamol, NSAIDS), information about
which will be captured via the 6 week questionnaire.
Participants randomised to night splints will receive a
splint to wear at night for 6 weeks. The splint immobi-
lizes the wrist in a neutral or slightly extended position
(20 degrees from neutral) in order to avoid movement of
the wrist, which increases carpal tunnel pressure [20].
The Promedics® Beta Wrist Brace (with CE Marking) is
designed to avoid restriction at metacarpophalangeal joints
and thumb, and the binding will ensure comfort to enhance
adherence to splint wearing. Each splint will be fitted ac-
cording to the size of the participant’s hand and arm using
standard splints of differing sizes. The wrist angle will be in
neutral position (between 0 and 20 degrees) to reduce
carpal tunnel pressures. No other types of therapy will
be permitted during the 6 weeks, except simple anal-
gesia prescribed by the treating clinician or bought over
the counter (e.g. paracetamol, NSAIDS), which will be
captured in the 6 week questionnaire.
Participants will be shown how to fit and remove the
wrist splint according to a standardised trial protocol.
Adherence will be encouraged and reinforced by verbal
instruction from the clinician on how and when to use
the splint and this will be supported by written information,
detailing care, fitting and use of the splint. Participants will
be instructed to perform gentle range-of-motion exercises
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when removing the splint to prevent stiffness. They will
also be given two Arthritis Research UK patient leaflets:
“Carpal tunnel syndrome” and “Splints for arthritis of the
hand and wrist”.
For participants with bilateral CTS, the non-study hand
will be treated according to normal clinical protocols in
use at the research site.
Outcome measures and endpoints
The primary endpoint will be at 6 weeks post randomisa-
tion and secondary endpoints will be at 6, 12 and 24 months
post randomisation. Table 2 explains which outcomes are
collected at the different time-points. The primary outcome
measure will be the overall score of symptom severity and
limitations in hand function as assessed by the BCTQ [21]
which has previously been shown to be highly reprodu-
cible, internally consistent, valid, and responsive to
clinical change in CTS patients [22, 23]. The BCTQ is
a disease specific questionnaire referring to a typical
24 h period in the last 2 weeks. It consists of two
subscales: symptom severity scale (SSS: 11 items) and
function status scale (FSS: 8 items), both scored on 1–5
point scales, with final scores for each dimension calcu-
lated as a mean score between 1 and 5. The overall score
is calculated as the mean of all 19 items. Higher scores
correlate with more severe symptoms and functional
impairment.
Secondary outcome measures include; BCTQ symp-
tom severity and function status subscales [21], hand-
wrist symptom intensity (0–10 numerical rating scale),
interrupted sleep, [24] self-reported adherence to splinting
where indicated (Likert scale modified from previous re-
search [25]), patients’ perceived benefit and satisfaction
with treatment (Likert scale modified from previous re-
search) [25], impact of CTS on work and other activities
(including work absence and reduction in work perform-
ance measured by a 0–10 rating scale), referral for surgery,
surgery, general health (EuroQoL EQ-5D-5L) [26], quality
adjusted life years, health care utilisation and patient
incurred costs, and use of co-interventions such as
Table 2 Outcome measures and data collection time points
Baseline measures Description Baseline 6 week
follow-up
6 month
follow-up
12 month
follow-up
24 month
follow-up
Demographics gender, date of birth ✓ ✓ ✓ ✓ ✓
Previous CTS episodes number of episodes and treatments ✓
Current CTS episode location and duration ✓
Participant preference and
expectations for treatment
Likert Scale adapted from previous research ✓
General Health Self-reported health and comorbidities ✓
Primary outcome measure
Hand/wrist pain and function Boston CTS questionnaire ✓ ✓ ✓ ✓ ✓
Secondary outcome measures
Hand/wrist pain intensity NRS (0–10) over last 24 h ✓ ✓ ✓ ✓ ✓
Interrupted Sleep Estimation of interruption to sleep scale ✓ ✓ ✓
Adherence with splinting Scales adapted from previous research ✓
Other Treatments received Self-reported referral to surgery and prescribed analgesia ✓ ✓ ✓ ✓
Satisfaction and experience Likert scales adapted from previous research ✓
Health economic outcomes
Health related quality of life EuroQoL:EQ-5D-5L ✓ ✓ ✓ ✓ ✓
Employment Current employment status and employer support ✓ ✓ ✓ ✓ ✓
Performance at work How performance at work is affected NRS 0-10 ✓ ✓ ✓ ✓ ✓
Work absence Self-report days absent from work ✓ ✓ ✓ ✓ ✓
Healthcare utilisation Primary care consultations ✓ ✓ ✓
Secondary care contacts including investigations
Prescribed medications
Use of private healthcare
Patient-incurred costs and use of
co-interventions
Over-the-counter medications or interventions ✓ ✓ ✓
Schedule of events
Chesterton et al. BMC Musculoskeletal Disorders  (2016) 17:415 Page 5 of 11
supplements and analgesia. Participants’ expectations re-
garding treatment response [25] and presence of bilateral
CTS symptoms will be explored as potential effect
modifiers.
Adverse events
Although Depo-Medrone is not specifically licensed for
use in CTS, it has been widely used for many years in
standard practice in both primary and secondary care
and has a very well established and understood safety
profile [27–29]. It is being used within the injection
protocol in accordance with the guidance given in the
BNF [28] for local inflammation in soft tissues and expert
opinion provided in Map of Medicine [27] regarding the
use of corticosteroid for CTS. The incidence of adverse
predictable undesirable side-effects associated with the
use of corticosteroids correlates with the relative potency
of the drug, dosage, and timing of administration and
duration of treatment, and therefore based on the
dosage to be used in this study, there is no require-
ment within this study to record non-serious adverse
events beyond normal clinical practice. Where a Serious
Adverse Event (SAE) or Suspected Unexpected Serious
Adverse Reaction (SUSAR) occurs, reporting procedures
are in place that are in accordance with good clinical
practice guidance and the requirements specified by the
MHRA. All SAEs will be considered by the external
monitoring committees.
Data collection methods
All participants enrolled in the study will be asked to
complete a paper questionnaire at the baseline clinical
appointment and again at 6 weeks, 6, 12 and 24 months
when a questionnaire will be posted to them. Question-
naires will capture data on all outcome measures. If the
questionnaire is not returned within 2 weeks of initial
mailing, a reminder will be sent (text message, e-mail, or
telephone call). If the questionnaire is still not returned, a
second follow-up questionnaire will be sent 4 weeks later.
For non-responders, minimum data collection (MDC)
to capture the primary outcome measures will be
undertaken by a research nurse by telephone at 2 weeks
after mailing of the second questionnaire. Where a
participant is not able to be contacted by telephone
within three working days, a postal MDC questionnaire
will be sent. Patients who do not respond or are not
contacted by telephone will still be sent subsequent
questionnaires at further follow-up time points unless
they request not to.
The flow events as participants proceed through the
trial is outlined in (Fig. 1) and the the timing of key
events outlined in Table 3.
Statistical analysis
Primary analysis at 6 weeks
Baseline characteristics will be summarized for the two
treatment groups using appropriate descriptive statistics.
The primary analysis will be conducted blind to treatment
allocation and will be analysed on intention to treat (ITT)
approach with all randomised participants retaining their
original randomised group. Multiple imputation using
chain equations [30] will be used to impute missing data.
Sensitivity analyses will be performed to compare ITT re-
sults to those based on complete-case analysis.
Multiple linear regression will be used to obtain the
mean estimates and 95 % confidence intervals for the
difference in the BCTQ overall score at 6 weeks between
the treatment groups adjusting for age at recruitment,
sex, duration of symptoms, and index score at baseline.
Secondary analyses (outcomes up to 6 months)
Using similar methods described for the primary analysis,
the effect of treatment will be estimated over the medium
term (6 months post-randomisation) as measured by the
BCTQ overall score, and also for the secondary outcome
measures listed above recorded at 6 weeks and 6 months.
Per protocol analyses, based on self-report adherence
to night splinting and use of a single injection, will be
carried out. No interim analyses are planned.
Potential effect modifiers, i.e. participants’ expectations
regarding treatment response and presence of bilateral
CTS, will be explored through adding moderator*treat-
ment interactions to the models estimating the primary
outcome of symptom severity and function (acknowledging
that interpretation of p-values will be placed in context of
anticipated low power as well as the exploratory nature of
the tests), and describing effects of treatment for subgroups
of patients defined based on modifying variables.
Sample size and calculation
Although previous studies using the BCTQ have pro-
vided information on the minimal important within-
group change (0.23 points) there is limited evidence to
underpin the definition of a minimum clinical important
difference between the expected effects of injections versus
night splinting for the primary outcome measure. Previ-
ously published RCTs have either examined the effective-
ness of injection or night-splinting in patients with CTS,
but very few have compared the two treatments. As both
the treatments in this trial are active, we would expect a
smaller difference between the treatment groups than if an
active were compared to a control group, where a mini-
mum of a 20 % difference might be expected. Hence, in
order to detect a 15 % greater improvement, as measured
by the BCTQ from an expected baseline value of approxi-
mately 2.9 points (scale 1–5, SD 1.0) [18, 31–33] in the in-
jection group compared to night-splinting (i.e. a 0.9-point
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Fig. 1 Flow of participants through the trial
Table 3 Participant timeline
Visits Screening Baseline and
intervention
Day 0
6 week
follow-up
6 month
follow-up
12 month
follow-up
24 month
follow-up
Diagnosis ✓
Eligibility Screening ✓
GP pathway only: Written Informed Consent for contact by Keele RN
and completion of Consent to Contact Fax Form
✓
GP pathway only: Keele RN telephone call to potential participant ✓
GP pathway only: Confirmation of Eligibility and Randomisation ✓
Informed consent by authorised local Investigator ✓
Participant Baseline Data self-report Questionnaires ✓
Web randomisation ✓
Administration of study intervention ✓
Participant self-report follow up Questionnaires ✓ ✓ ✓ ✓
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(30 %) reduction in the injection group versus a 0.45-point
(15 %) reduction in the night splinting group, with pooled
SD of 1.0, SMD 0.45), we would need complete data for
200 patients (100 in each treatment group) given approxi-
mately 90 % power and 5 % two-tailed significance. By
adopting an initial sample size that would take account of
15 % loss of data (which we achieved in previous similar
studies), we would need to recruit 120 participants per
treatment group, 240 patients altogether. Through routine,
6-monthly examination of the follow-up rates, as part of
the reporting for the Trial Steering and Data Monitoring
Committees, we will be able to examine the deviation of
the observed attrition rate from the expected 15 % factored
into the sample size calculation.
Outcomes across the 24-month follow-up period
A repeated measure analysis using data from the four
follow-up points (6-week, 6-, 12-, and 24-months) will
be undertaken with two key clinical outcomes (BCTQ
overall score and hand/wrist pain intensity NRS) to
examine differences in the two treatment groups over
the whole follow-up period. Additionally, the cumulative
number of participants who report on the self-complete
questionnaires that they have been i) referred for CTS
surgery or ii) undergone CTS surgery will be examined
by treatment group.
All analyses will be performed using STATA 14. Statis-
tical estimates will be accompanied by associated 95 %
confidence intervals and all p values <0.05 considered to
indicate statistical significance.
Health economics
The base-case economic analysis will adopt an NHS and
personal social services (PSS) perspective, as recommended
by the NICE reference case for economic evaluations [34].
However, a sensitivity analysis will also be undertaken to
consider a wider societal perspective, where all relevant
costs are measured, including direct health care costs
incurred within both public and private sectors, and the
indirect costs outside the health care sector associated with
productivity loss (absenteeism). The primary economics
analysis will be a cost-utility analysis to enable comparisons
to be drawn with other areas of health care; utility will be
measured using quality-adjusted-life-year (QALY) values
which will be derived from the EuroQoL EQ-5D-5L. A
cost-effectiveness analysis will also be carried out using
change in the total BCTS score as the measure of outcome.
Results will be presented for the medium-term using data
for the first 6 months and long-term, using data for all
24 months of follow-up.
Data on health care resource use, time off work and
presenteeism/performance will be obtained from the
participant questionnaires at 6, 12 and 24 months. Par-
ticipants will be asked about primary and secondary care
contacts, investigations, treatments and surgery over-the-
counter purchases, and prescriptions. Health care resources
associated with delivery of the interventions will also be de-
termined. NHS care will be costed as national averages with
inpatient and outpatient episodes costed using NHS refer-
ence costs [35, 36]. Due to the paucity of high-quality unit
cost data for private health care consultations these data
will be costed as the NHS equivalent. The British National
Formulary (BNF) will be used to cost prescribed medication
[28]. Costs of absenteeism from paid work will be estimated
by multiplying the reported number of days off work by the
average daily wage, stratified by hourly mean income
according to gender, full/part-time work status and
standard occupational classification (SOC 2010) [37].
The human capital approach to calculating productivity
costs will be used, with the friction cost approach used
in a sensitivity analysis.
Cost data alongside trials are invariably skewed. We
will calculate 95 % confidence intervals (CIs) around differ-
ences in mean costs, EQ-5D scores, QALYs, and changes
on the Boston CTS questionnaire using conventional para-
metric methods and non-parametric bootstrapping (5000
replications) [38]. The total QALYs per patient will be
calculated using the area under the curve method, with ad-
justment for difference in baseline utility scores if required
[39]. Multiple imputation will be employed where there is
missing cost and/or outcome data.
The aim of the economic evaluation will be to estimate
and compare the difference in costs of corticosteroid in-
jection compared with night splinting and relate this to
the difference in outcomes of injection versus splinting.
An incremental approach will be used in the analysis,
with differences in costs and QALYs expressed as an
incremental cost-effectiveness ratio (ICER) - cost per add-
itional QALY gained. Similarly for the cost-effectiveness
analysis, we will analyse the incremental cost per 1-point
improvement in total BCTS score. The robustness of the
results will also be explored using deterministic sensitivity
analysis. This will explore uncertainties in the trial based
data itself, the methods employed to analyse the data and
the generalisability of the results to other settings. Uncer-
tainty in the confidence to be placed on the results of the
economic analysis will be explored using probabilistic sen-
sitivity analysis. Bootstrap samples are used to compose
cost effectiveness/utility planes (which graphically show
the variability in the data) and cost effectiveness accept-
ability curves are plotted to quantify, from the bootstrap
data, the probabilities of the interventions being cost ef-
fective across a range of ceiling values (otherwise referred
to as the willingness-to-pay threshold values).
Timing of analysis
The primary analysis to examine the clinical and health
economic outcomes will be blinded to treatment and
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completed after the final 6 month follow-up questionnaire
has been received. The treatment allocation will be un-
blinded once this analysis has been completed in accord-
ance with the agreed analysis plan. The analysis of the 12
and 24 month data will be analysed after the final 24 month
follow-up questionnaire has been received and will not be
blind to treatment allocation. No interim analyses will be
performed.
Discussion
This paper describes the design of pragmatic rando-
mised trial which investigates the comparative clinical
and cost effectiveness of corticosteroid injections and
night splints in reducing symptoms and improving
hand function in mild to moderate CTS over the short
(6 weeks), medium (6 months) and long term (24 months).
A number of issues have been addressed in the design of
this study.
In terms of diagnosis there is a fundamental problem
in a lack of an accepted “gold standard.” Furthermore CTS
is routinely classified as mild, moderate or severe although
criteria are not well established [19]. Many studies have
been undertaken to evaluate diagnostic tools and tests for
CTS, [40–45] most of which have been carried out in sec-
ondary care on patients with severe symptoms, using either
neurophysiological testing, expert clinical opinion or
surgical outcomes as reference standard. The American
Academy of Orthopaedic Surgeons (AAOS) have published
guidelines on the diagnosis and management of CTS and
suggest that the most reliable approach for clinical diagno-
sis includes neurophysiological tests, structured history
taking and physical symptoms coupled with the patient
self-report hand diagram [29]. This is not universally ac-
cepted and there is considerable controversy as to the need
for neurophysiological testing in carpal tunnel syndrome
diagnosis. Neurophysiological studies are often used in sec-
ondary care especially prior to surgical intervention or in
severe clinical presentations. However neurophysiological
studies do not always correlate well with clinical severity
and have not been shown to accurately predict outcomes
for patients with mild to moderate CTS. Primary care ac-
cess to nerve conduction studies is variable throughout the
UK. As such these investigations are usually reserved for
equivocal diagnoses and are not currently required rou-
tinely in this setting for mild/moderate cases to guide deci-
sions regarding initial conservative treatments [46].
For the purposes of this trial it was therefore necessary
to develop a tool to standardise the diagnosis of CTS pre-
senting in Primary care. A Delphi technique study was
undertaken to seek the opinions and usual practice of
GP’s with an interest in musculoskeletal medicine. Forty
five GPs with an interest in hand research were identified
from the Primary Care Rheumatology Society. The opin-
ions of panel members were sought through three rounds
of questionnaires, distributed anonymously, using an on-
line survey website between October 2011 and January
2012. A clinical consensus meeting was held at the end of
the study to finalise the tool which was then disseminated
for approval and any further comments. The consensus
exercise resulted in a clinical diagnostic tool that can be
used to standardise the diagnosis of CTS for both trial
purposes and in clinical practice, designed specifically for
use in primary care [12].
Eligibility criteria were defined to recruit a representa-
tive primary care population of mild to moderate CTS pa-
tients, protect patient safety and also to ensure maximum
generalisability of the results to primary care. Accordingly
we chose to include patients with well controlled diabetes
and thyroid disease because. Routinely in general practice
patients with well controlled diabetes and thyroid disease
will be offered the study treatments.
Whilst conducting the trial in a setting that is very close
to primary care is crucial to our research question and to
optimizing the generalisability of the findings, we recog-
nised the need to maximise recruitment and achieve real-
istic recruitment targets. Therefore we decided to use as
recruitment sites, musculoskeletal services which receive
direct referrals from multiple general practitioners who
themselves do not inject CTS patients. By strictly applying
the eligibility criteria we can demonstrate the study popu-
lation is still representative of the target population.
Although corticosteroid injection is a commonly used
primary care intervention, there may be potential risk of
harm which includes median nerve damage, infection
and tendon rupture. While the incidence is extremely
low and evidence mostly based on case descriptions this
risk in this trial will be limited by; restricting the interven-
tion to a less powerful corticosteroid (20 mg of Depo-
Medrone), limiting the number of permissible injections to
one in the 6-week treatment period, excluding patients with
injections in the past 6 months and careful clinical assess-
ment to ensure exclusion of patients at risk of an adverse
event. Adverse events associated with interventions will be
monitored via patient report to their GPs, case report forms
and patient self-report questionnaires. GPs will be trained
in reporting of serious adverse events and SUSARs as part
of training in the study protocol.
Clinical relevance of this trial and importance of the
question
This paper describes the rationale and design for the first
randomised pragmatic trial that aims to determine the
comparative effectiveness of two commonly used inter-
ventions for patients with mild to moderate CTS. No pre-
vious trials have directly compared these treatments for
CTS in primary care populations or reported on clinical
effectiveness beyond 6 months. Comparative cost
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effectiveness of the interventions has not been investi-
gated. The proposed trial will make an important contri-
bution to the evidence base available to support effective
conservative management of CTS in primary care and will
inform both patient management and future research for
treatment options for CTS.
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